Recent Analysts’ Ratings Changes for Astrana Health (ASTH)

Several brokerages have updated their recommendations and price targets on shares of Astrana Health (NASDAQ: ASTH) in the last few weeks:

• 8/16/2026 – Astrana Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/10/2026 – Astrana Health had its price target raised by Truist Financial Corporation from $47.00 to $55.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Astrana Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Astrana Health had its price target raised by Barclays PLC from $50.00 to $53.00. They now have an “overweight” rating on the stock.
• 7/14/2026 – Astrana Health had its price target raised by TD Cowen from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Astrana Health had its price target raised by BTIG Research from $50.00 to $65.00. They now have a “buy” rating on the stock.

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.